Equities analysts expect Oragenics, Inc. (NASDAQ:OGEN) to announce ($0.07) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Oragenics’ earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.06). Oragenics reported earnings of ($0.38) per share during the same quarter last year, which would indicate a positive year over year growth rate of 81.6%. The firm is expected to announce its next quarterly earnings results on Monday, August 12th.

On average, analysts expect that Oragenics will report full year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.28). For the next year, analysts expect that the company will report earnings of ($0.27) per share, with EPS estimates ranging from ($0.31) to ($0.23). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Oragenics.

Oragenics (NASDAQ:OGEN) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.03).

Separately, HC Wainwright restated a “buy” rating on shares of Oragenics in a report on Friday, April 26th.

NASDAQ OGEN traded up $0.01 on Monday, hitting $0.48. 370,840 shares of the company were exchanged, compared to its average volume of 1,324,356. The company’s 50 day moving average price is $0.48. Oragenics has a twelve month low of $0.38 and a twelve month high of $3.74.

About Oragenics

Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Read More: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Oragenics (OGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.